10 results about "Immunogenicity" patented technology

The invention provides a monocytic leukemia associated antigen MLAA-34 resistant fully human monoclonal single-chain antibody ScFv. The monoclonal single-chain antibody ScFv of special anti-MLAA-34 is obtained by screening and identifying in a phage antibody library; MLAA-34 protein is firstly expressed and purified, and antigen protein is provided for monoclonal antibody preparation. A method beneficial to genetic engineering is used for screening and identifying anti-MLAA-34 fully human monoclonal antibody. The fully human monoclonal single-chain antibody ScFv for specially combining and efficiently expressing tumor cell strains of MLAA-34 is obtained. The fully human monoclonal single-chain antibody ScFv can be used for solving the immunogenicity problem of a mouse original antibody, and the single-chain antibody ScFv is formed by connecting a heavy chain and a light chain of an antibody variable region, is small in molecular weight, is high in penetrating power and is more beneficial to application.

The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

The invention relates to an oral cavity defect repair membrane and a preparation method thereof, in particular to an acellular matrix material and preparation thereof, and the application in the repair of oral cavity defect. The preparation comprises: (1) taking the porcine small intestine jejunum segment, cleaning, radial cutting, removing the mucosa layer, sarcolemma layer and serosa layer, andobtaining the porcine small intestine submucosa tissue membrane; (2) soaking the tissue membrane of the porcine small intestine submucosa obtained in the step (1) in peroxyacetic acid solution or sodium hydroxide solution, and take out and cleaning to obtain an acellular matrix of the porcine small intestine submucosa tissue; (3) soaking the porcine small intestinal submucosa tissue obtained in the step (2) with a dopamine solution, sterilize, and obtaining an acellular matrix material. The invention can avoid the loss of cell growth factor in the tissue membrane of the porcine small intestinesubmucosa, ensure the the obtained acellular matrix material has better tissue micropore structure and mechanical properties, and can meet the needs of oral bone injury repair; low immunogenicity andgood safety.

The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.

The invention provides an IsdB antigen epitope peptide for diagnosing or preventing staphylococcus aureus infection. The IsdB antigen epitope peptide comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO: 8. The invention also provides an application of the antigen epitope peptide in preparation of drugs for diagnosing, preventing or treating staphylococcus aureus infection. According to the present invention, an antibody dominant epitope peptide of iron-regulated surface determinant B of staphylococcus aureus is determined through screening and has strong immunogenicity. The dominant epitope peptide has amino acid sequences that are conservative in a variety of S. aureus strains, so that the dominant epitope peptide can be used in preparation of diagnostic reagents against staphylococcus aureus infection. The IsdB antigen epitope peptide can also be used for preventing or treating other S. aureus infections.